Haolan Yu
Shanghai, 200433, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Mechanistic Insights Into Immune Cell Dysregulation Mediated by Novel Heterozygous Variants in CARD11 and MALT1.
Journal: Journal of clinical immunology
Published: July 28, 2025
B4GALNT4-Mediated Glycosylation of PDK1 Activates the PI3K-AKT Signaling Pathway to Promote Prostate Cancer Progression.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: June 18, 2025
Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 25, 2024
Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma.
Journal: Journal of medicinal chemistry
Published: February 13, 2024
Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction.
Journal: Cell reports. Medicine
Published: November 22, 2023
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
Journal: Journal of medicinal chemistry
Published: June 28, 2021
TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in Prostate Cancer Cells.
Journal: Molecular cancer research : MCR
Published: June 08, 2020
MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies.
Journal: Medicinal research reviews
Published: June 01, 2020
Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Journal: Theranostics
Published: April 28, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026